Get started

PFE

Pfizer, and why you keep old notesI got an alert on Pfizer NYSE:PFE just now that on the 30m a Tradingview Spike Alert I had setup fired. This is following research I did over the weekend to the Support level that PFE reached in the recent down move. While doing that I found an old annotation from November 2020 earnings that informed a long term dividend investment play. It's nice to see how something has performed over the long term to remind an investor to buy and hold good companies. The company has earnings tomorrow.
NYSE:PFE
by norok
1
The Week Ahead: TWTR, UAA, GPN, PFE Earnings; ARKK, XBI, XRTEarnings Announcements in Options Liquid Underlyings with >70 rank and >50% 30-Day Implied: TWTR (93 rank/90 30-day implied) (Thursday, before market open) UAA (80/68) (Friday, before market open) GPN (71/51) (Thursday, before market open) PFE (76/42) (Tuesday, before market open) Pictured here is a directionally neutral TWTR short strangle paying 1.34 on a buying power effect of 3.71 (on margin), 36.1% ROC at max; 18.1% at 50% max. It announces earnings on Thursday before market open, so look to put on a play in the waning hours of Wednesday's session if you want to take advantage of the ensuing volatility contraction post-announcement on Thursday. For those more of a defined risk bent, consider the February 18th 25/30/44/49 iron condor, paying 1.14 at the mid price as of Friday's close on buying power effect of 3.86, 29.5% ROC at max, 14.8% at 50% max with 2 x expected move break evens. UAA is probably small enough to short straddle/iron fly, with the February 18th 19.5 short straddle paying 2.42 on buying power of 3.93 (on margin), 61.6% ROC at max, 15.4% at 25% max. The risk one to make one iron fly would be a "stays within the expected move" sort of play with the February 18th 15.5/19.5/19.5/23.5, paying 2.03 on 1.97, 103% ROC at max; 25.8% ROC at 25% max. The GPN February 18th 130/160 short strangle was paying 2.97 on buying power of 14.97 as of Friday's close, 19.8% ROC at max, 9.9% at 50% max. The bid/ask is showing wide in after hours, and I don't particularly like the five wides where I want to pitch my tent. This is probably why I haven't bothered to play it before. Although PFE's 30-day is a bit <50%, I figured I'd price out a setup because of its high options liquidity. Unfortunately, it's not very compelling at the moment, with the 16 delta 48.5/58.5 in the February 18th contract paying a scant .89 on buying power of 6.12 as of Friday's close -- 14.5% ROC at max, 7.3% at 50% max. Exchange-Traded Funds With Ranks >50 and 30-Day IV >35%: ARKF (76/63) XBI (71/45) ARKK (70/67) ARKG (70/65) XRT (63/46) KWEB (63/54) SMH (60/41) GDX (50/45) Pick your Cathie Woods poison (ARKF, ARKK, ARKG), I guess. Otherwise, sell premium in XBI or (there's one I haven't seen in a while) ... XRT, although you're probably going to get more bang for your buck out of KWEB, with its higher 30-day. Broad Market Exchange-Traded Funds, Ordered By Implied Volatility Rank: QQQ (55/29) IWM (54/30) EFA (43/19) SPY (41/22) DIA (40/21)
NYSE:TWTR
by NaughtyPines
$PFE - Downtrend Reversal - 4 Day Inside Bar - Upcoming CatalystNYSE:PFE A hammer signaled reversal for $PFE. Shortly after price broke out of the downtrend resistance. Four inside bars have formed during period of consolidation. $PFE looks primed for sharp movement. Catalyst would likely be FDA / CDC approval/rejection of its Covid vaccination for children, expected in 4th week of Feb. Application is for 2 doses, though 3 would be required. Application and study for 3rd shot are expected to be submitted during the initial application review phase. This is one ticker to be aware of. Biased long, but willing to play both sides.
NYSE:PFELong
by TheGritz
Pfizer | Fundamental Analysis | MUST READ | LONG 🔔Historically, Pfizer has not had much momentum when it comes to stock performance. Over the past ten years, the S&P 500 Index has outperformed this large pharmaceutical company. But now Pfizer is gaining momentum. Last year it outperformed the benchmark index - Pfizer was up 60%, while the S&P 500 was up 27%. And today's Pfizer doesn't look much like Pfizer did a few years ago. In 2020, the company completed the separation of its Upjohn business, eliminating an element that was driving down revenues. Today, Pfizer has many "best sellers," a new coronavirus drug, and a full development cycle. So is it worth investing in this drug maker in 2022? First, let's look at the company's Covid business. Pfizer is a leading supplier of vaccines in many parts of the world. In the U.S., the company has fully vaccinated more than 118 million people. But overseas, Pfizer's vaccine business is actually even bigger. The company claims that it generates 75% of its revenues from vaccine sales outside the United States. The European Union recently exercised an option to supply more Pfizer vaccines, bringing the total number of doses of Pfizer vaccines to be delivered this year to over 650 million. The full agreement, signed last spring, calls for up to 1.8 billion doses to be delivered to the region by 2023. In Pfizer's latest earnings report, the company projected vaccine revenue of $36 billion for all of 2021. But this year could turn out to be even more successful for Pfizer than last year. Here's why. Vaccine orders remain high -- but with the addition of a new coronavirus product. Late last year, Pfizer received approval for the emergency use of Paxlovid, an oral coronavirus treatment. Paxlovid is a pill that should be given at the first sign of infection. The drug's main ingredient blocks the action of an enzyme necessary for the coronavirus replication process. The U.S. has ordered 20 million courses of Paxlovid treatment, and the U.K. has ordered 2.75 million. SVB Leerink analyst Geoffrey Porges predicts that Paxlovid will generate more than $24 billion in revenue this year and $29.7 billion in vaccines, according to FiercePharma. That amounts to more than $50 billion in revenue from the coronavirus program alone. Of course, investors are most concerned about what will happen to these revenues in a post-pandemic world. Right now, it's impossible to accurately predict the level of revenue from the coronavirus program in the future. And that represents uncertainty. Nevertheless, experts say the coronavirus will exist. And that means we will need remedies and treatments. So we can probably expect a satisfactory level of revenue from coronavirus-related products for quite some time. But here's the best news: Pfizer is far from being a coronavirus-only company. The company's nine-month earnings report shows that at least six products are generating blockbuster revenue. And in the third quarter, the company says, revenue excluding the coronavirus vaccine rose 7 percent to more than $11 billion. As if that weren't enough, Pfizer has something else to like. And that's the pipeline. The company is working on 94 programs -- 29 of which are in Phase 3 and nine of which are in the registration phase. That means we may see a new batch of drugs in the not-too-distant future. This is important because the patent on some of Pfizer's drugs expires at the end of this decade. The blood-thinning drug Eliquis, for example, will lose protection in 2028. This is a standard part of life for a pharmaceutical company - and that's why it's important to have a strong product portfolio to make up for future patent expirations. Now let's look at the valuation. As mentioned earlier, Pfizer's stock price has risen slightly. But it is still trading at very reasonable levels. It trades at only 8.5 times projected earnings. In addition, Pfizer pays a solid dividend, with a yield of over 2.8%. So should you invest in Pfizer in 2022? Well, now seems like a good time to do so. The company generates billions of dollars in revenue from its coronavirus vaccine program. It has a portfolio of non-coronavirus drugs and a full cycle of late-stage research. The stock looks inexpensive -- and an investment in this major pharmaceutical player will provide you with passive income in the form of dividends. All of this is a great formula for success this year and in the years to come.
NYSE:PFELong
by FOREXN1
4
Pfeizer reversing. PFECOViD paranoia did great things for the pharma industry, including and especially Pfeizer. But, even then, nothing can grow forever. South Sea, East India and Pfeizer are no exceptions. The usual divergence with specific wave cycle finished. Highly, highly suspect for a reverse. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NYSE:PFEShort
by Rykin_Capital
Pfizer (PFE) to continue its BULL run in 2022!Fundamental Analysis Pfizer, Inc. has consistently been one of the largest pharmaceutical companies in the world for the better part of the last two decades. The company has a remarkable history going back all the way to the year 1849, when Pfizer was founded in Brooklyn, New York. The large cap pharma giant has developed a well-balanced and deep portfolio of products in key areas like Inflammation and Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines etc. However, it seems that as a result of the success of Pfizer's vaccine COVID-19 treatments, many investors have forgotten about the rest of Pfizer's business and how successful it continues to be. It is true that the sales of its COVID-19 vaccine ($36 billion in 2021 alone) have managed to nearly double Pfizer's annual revenue from $41.9 billion in 2020 to over $78 billion in 2021. What's even more important is that the strong sales growth has also translated into higher profits for the company as its profit margins before interest and taxes, referred to as EBIT margin, have risen over the past year. This shows that Pfizer has managed its R&D and all other fixed and operating costs associated with development, production and distribution efficiently, thus improving the profitability ratios of the company. The large cap pharma giant has also managed to almost triple the size of its free cash flow to more than $29 billion over the past twelve months compared to only $11.6 billion in 2020. More free cash flow makes a business more robust, giving Pfizer more money to invest in research and development of new products, pay more in dividends, or strengthen its balance sheet. The company currently has a total of 94 drugs in the pipeline spread across critical treatment areas like Inflammation and Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines etc. all waiting regulatory approval. - Phase 1(27); Phase 2 (29); Phase 3 (29); Registration (9) Looking at the outstanding track record of Pfizer's drug development capabilities, we can easily state that the company will continue to be a leader in the sector that it operates in. Macro view The equity markets in the US are currently undergoing a process of meaningful repricing and re-valuation of what companies are actually worth, as everyone is getting ready for the Federal Reserve to start raising interest rates in the US and tighten its monetary policy. In a rising interest rate environment, investors tend to move away from expensive high-growth stocks trading at unreasonably high P/E and P/S valuations as the tighter monetary policy environment makes it much more difficult and more expensive for such companies to borrow and invest capital and produce the high earnings growth that investors expect from them. Well-established large cap Healthcare and Biotech stocks are considered to be least correlated with the monetary policy situation in the country as they tend to trade more on FDA drug approvals and drug-related announcements rather than actual earnings per share. Most of the leaders in this space also have a substantial pricing power, as people using their medicines are doing so because they need them and because the drugs are helping them get better. Thus, owning Healthcare and Biotech stocks in a rising inflation and interest rate environment is a defensive play that could end up paying off big time, as stocks in these sectors are rather volatile. Technical Analysis The stock has experienced a volatile retracement from its $61 all-time highs and is currently in a corrective phase. However, the uptrend is still intact as the price is well above both the strong horizontal support at $51 and the upward sloping diagonal support (blue line) at $44. Furthermore, the stock is trading above its 5, 20, 50, 200 EMAs, which is also a bullish continuation signal. We expect buyers to start coming in around the $52-53 level, thus establishing the next higher high. Once that is done, the stock will re-test its ATH at around $61 in Q1 of this year. The broad market framework, together with the many positive company related developments in the coming months are expected to bring enough momentum to the stock in order for it to break its previous ATH and set a new one sometime in Q2. Our target for the stock in H1 of 2022 is around the $68 level, which is roughly 30% higher from the current levels. Follow and Copy us on eToro for more detailed market analyses, profitable trading ideas and a consistent portfolio performance. [ b] Sincerely, @DowExperts
NYSE:PFELong
by DowExperts
Pfizer | Fundamental Analysis | LONG SETUP ⚡️Pharmaceutical giant Pfizer has been at the forefront of the industry, developing drugs to treat COVID since the pandemic began. Unfortunately, the world continues to struggle with different strains of the virus, most recently with the Omicron variant, but Pfizer's products are still in high demand, which will likely boost its results in 2022. It's been about a year since the first COVID vaccine became available in the U.S., and a race has begun to ramp up production and dose distribution. Several companies have been working on vaccines, but the market has become a two-company market. The vast majority of the doses administered in the U.S. came from Pfizer and Moderna, two companies that developed vaccines using mRNA technology. Pfizer and Moderna have developed mRNA vaccines that use the genetic code of the virus to trigger an antibody response in the human body. Traditional vaccines use an attenuated form of the whole virus, which teaches the body to defend itself against it. This is essentially similar to how the body develops immunity after a person gets chickenpox, but the weakened virus does not make the person sick. Both types of vaccines achieve similar results, but pharmaceutical companies can reproduce the genetic code for production faster and easier than the virus itself. Demand for the vaccine has increased primarily because of the ability of the virus to mutate into new variants. Initially, Pfizer's vaccine was supposed to treat with two doses, but as new variants emerged, many began to give a third shot (called a booster). Pfizer's original 2021 forecast called for 1.3 billion doses, but it ended up producing about 3 billion doses in 2021. Now, the company's management predicts that Pfizer will produce about 4 billion doses in 2022. This is a tragic and challenging time for society as the pandemic continues, but Pfizer's leadership position has created tremendous benefits for the company. First, the actual sales of its vaccine have been enormous: The company's expected revenue in 2021 was $36 billion. By comparison, Pfizer's 2020 revenue was $41.9 billion; this means that the COVID vaccine nearly doubled Pfizer's business! What's more, it was profitable for Pfizer. The company's earnings before interest and taxes, called EBIT margin, increased over the past year as the vaccine business grew. The company has also significantly increased free cash flow, which was more than $29 billion in the past twelve months, up from $11.6 billion in 2020. Increased free cash flow makes the business more sustainable, which gives Pfizer more money to invest in research and new product development, pay dividends, or strengthen its balance sheet. As the Omicron option spreads, it is becoming more likely that COVID will not disappear entirely shortly. Pfizer recently developed an oral antiviral pill to treat early-stage COVID symptoms, and company executives estimate that 80 million courses of treatment could be produced in 2022. Although our focus today is on the next twelve months, Pfizer could potentially profit from the COVID treatment for several years. Investors have reacted to Pfizer's COVID success; the company's stock is up 56% in the last year, a big gain for a company with a market value of $329 billion. Still, the market may not be valuing Pfizer highly enough. If we want to value a stock by the amount of free cash flow that investors receive per share, we can look at the free cash flow yield; this percentage reflects how much of the stock price investors receive in free cash flow. We want to get as much free cash flow for our money as we can because it pays dividends, funds new products, and generally creates value for shareholders - it's like the "lifeblood" of a company. Accounting or non-cash items can affect earnings, so free cash flow can provide a fresh perspective on stock valuation. Pfizer's increase in free cash flow this year resulted in higher returns because free cash flow grew faster than the stock price. Now that the stock has started to rise, yields are down, but we are still near multi-year highs, which means that the stock offers you more "value for your money" than it has for most of the last ten years. In other words, they are still cheap. With COVID firmly entrenched in our world, Pfizer retains its chances of success in 2022.
NYSE:PFELong
by FOREXN1
4
711 - Desperados: Momentum/Trend Cloud @ 7 - 12% correction to well over 23% on Trend... extremes. Notice how Momentum has fallen below Trend. A Picture of health or dysfunction. IV AAPL @ 61% TSLA @ 63% NVDA @ 77% AMD @ 88% and Beacon of Safety PFE @ 85% Baba is now 90% Pfizer is extreme as is Baba. These are all later stage readings for Implied VX. _____________________________________________________ All signs of a Shorter Term process of carving out a High prior to the Ice Bucket challenge from the Federal Reserve.
NASDAQ:META
by HK_L61
5
$PFE keep an eye on it.$PFE has been trending up for the past few weeks. mostly probably because of the covid variant and news. today it just reach the ATH and could possibly continues when they release a news for oral medication for covid. average move of this stock is about .70 to $2.00 depending on a day. on a smaller time frame, the momentum is almost reaching the exhaustion. possible Put play tomorrow as people take profits after reaching all time high. Hello Guys, welcome to this free and technical analysis. ( mostly momentum play ) I am going to explain where I think this stock is going to go over the next day or week play and where I would look for trading opportunities. If you have any questions or suggestions which stock I should analyze, please leave a comment below. If you enjoyed this analysis, I would definitely appreciate it, if you smash that LIKE button and maybe consider following my channel. Thank you for watching and stay tune.
NYSE:PFEShort
by CHRIS_B58
2
Pfizer | Fundamental Analysis | LONG SETUP | MUST READ 🔔Some people say that the Chinese word for "crisis" is composed of two characters, one meaning "danger" and the other meaning "opportunity. In fact, this is not the case. Nevertheless, the word often hits the mark. While many crises carry danger, they also often present opportunities. In the case of COVID-19, we can certainly see this happening. To date, more than 5 million people worldwide have died from this viral infection. At the same time, numerous businesses made a lot of money during the pandemic by selling personal protective equipment, tests, therapies, and vaccines. None of them benefited more financially than Pfizer. In the third quarter alone, the company reported $13 billion in sales of its COVID-19 Comirnaty vaccine. SVB Leerink analyst Jeffrey Porges estimates that Pfizer expects to make a staggering $131 billion on sales of the COVID-19 vaccine by the end of next year. But is this pharmaceutical company stock worth buying? Let's first look at how Pfizer could make $160 billion on coronavirus over the next two years. First, we need to consider the company's projected revenue of $36 billion in 2021 from Comirnaty. Porges believes that sales of the vaccine will actually be much higher this year. He expects that approvals and authorizations in many countries for booster doses and for children could boost Comirnaty's total worldwide sales to $59 billion in 2021. The Wall Street analyst expects vaccine sales to drop to about $48 billion next year. So by the end of 2022, Pfizer's revenue from Comirnaty sales will be $107 billion. But Comirnaty probably won't be Pfizer's only source of revenue from COVID-19. The company hopes to soon get emergency approval and approval for the oral antiviral drug Paxlovid in the U.S. and other countries. Purges predicts that sales of Pfizer's COVID-19 pills could be about $95 million this year and $24 billion next year. If you add it all up, Pfizer's total revenue from COVID-19 sales would be about $131 billion over two years. Pfizer shares the profits from the sale of Comirnaty with its partner BioNTech. Although the company's revenue will be huge, its profits from the vaccine will not be as large. Sales of the COVID-19 vaccine are also likely to be lower in 2023. Porges, however, predicts that Paxlovid sales will grow to $33 billion in 2023. After 2023, though, the picture becomes less cheerful. Many investors speculate that COVID-19 will be like the flu, requiring annual vaccinations. But it is too early to judge whether this will actually be the case. If not, Pfizer's revenues will fall markedly over the next few years. Looking ahead, Pfizer faces a patent cliff beginning in 2026. Several of the company's currently best-selling drugs will lose patent exclusivity in the second half of this decade. Despite these potential problems, it should be noted that there are three reasons why Pfizer stock is still worth buying. Let's start with the most compelling one on the list, the dividend. Currently, Pfizer's dividend yields just under 3%. Given the cash flow the company will generate, there is a good chance that the dividend will increase. Pfizer is also predicted to use its growing cash reserves to make business development deals. The company is expected to license more promising drugs developed by other drugmakers. In addition, many believe that Pfizer will make a major acquisition in the not-too-distant future. The right deals could go a long way toward offsetting the impact of the patent cliff, which is looming in a few years. Finally, there is the possibility that sales of Comirnaty (or its successors) and Paxlovid will remain strong for a long time to come. COVID-19 could become endemic and bring Pfizer much more money over the next decade than anyone expects. Given that Pfizer made $13 billion on sales of its coronavirus vaccine in the third quarter alone, it's understandable why investors are wary of the rapidly evolving threat posed by the new variant, dubbed Omicron. If Omicron proves to be as insidious as early reports suggest, it could well become a serious problem for vaccinated people and vaccine manufacturers worldwide. But the fear of Pfizer's defeat of Omicron is quite premature. In fact, there is probably no company in a better position to solve such a problem as a new option, as an opportunity to rise to the next level. The dangers of this crisis may not go away. And the opportunities for Pfizer may not disappear either.
NYSE:PFELong
by FOREXN1
5